Broad applications in cell based assays, ranging from cell therapy and regenerative medicine to drug discovery and diagnostics.
Label-free high throughput characterization and isolation of cell populations based on machine-predicted labels without the use of physical surface markers or stains.
Label-free Monitoring and Isolation of
Our Solution for Cell Therapy
Conventionally, surface markers or stains have been necessary to characterize and isolate target cells in the cell manufacturing process by applying ViCS, we can characterize and isolate cells at high throughput without the use of molecular labels, and instead with machine predicted “in-silico” labels. Our technology can classify and isolate cells based on such apparent morphological differences as those between live and dead cells, activated and resting T cells, and differentiated and undifferentiated stem cells; as well as more subtle morphological variances in cells and organelles including cell-cycle phases, glycolytic levels, and apoptotic status. This technology is highly compatible with automated manufacturing processes since the label-free cell characterization eliminates a sampling step, thereby allowing inline measurements and enrichments in the manufacturing process.
Examples of distinguishable cellular phenotypes by ViCS
- Low Glycolysis
- High Glycolysis
Key Advantages of Our Technology
- Label-free process
- Cells can be characterized and isolated without the use of molecular labels, ideal for automated cell manufacturing
- Closed system
- Cell monitoring and isolation processes are performed within a sterile and closed system
- High throughput
- Image-based cell sorting at a high throughput rate, over 3,000 cells per second
- New imaging “biomarkers”
- Image-based profiling and isolation of cells lead to new biological findings
Drug Discovery /
Pooled high content phenotypic screens of genes and drugs compatible with multiple libraries including CRISPR gRNAs, shRNAs, antibodies, and even small compounds.
GET IN TOUCH
Interested in our technology?
Contact us to be part of our early access program.